Do nocturnal glycemic swings trigger stress hormones that disrupt sleep in people with insulin resistance?

Mechanistic explanations

• Hormonal cascades: Nocturnal glycemic drops act as acute stressors, triggering a counter-regulatory response that releases fast-acting catecholamines (such as adrenaline/epinephrine) and slower-acting glucocorticoids (such as cortisol) via HPA-axis activation to restore euglycemia.
• Sleep architecture disruption: Elevated overnight adrenaline and cortisol promote sympathetic nervous system dominance, causing tachycardia, micro-arousals, and transitions into lighter sleep stages. This fragmentation can initiate a bi-directional loop, as sleep disruption itself further elevates sympathetic drive and worsens glucose regulation.
• Metabolic destabilization: In insulin-resistant states, impaired hepatic insulin signaling prevents the necessary overnight suppression of gluconeogenesis and glycogenolysis. This is compounded by blunted peripheral muscle glucose uptake and elevated free fatty acids, which collectively destabilize overnight glycemic control.

Clinical evidence and complexity

• Cohort-specific variations: The clinical relationship between insulin resistance and glycemic variability depends on disease and treatment status. In insulin-treated cohorts (such as type 1 diabetes), lower insulin sensitivity strongly predicts higher glycemic variability. However, in non-diabetic insulin-resistant cohorts (such as women with polycystic ovary syndrome), insulin resistance is often associated with a lower relative coefficient of variation (CV) despite higher mean glucose levels, illustrating that therapeutic regimens and metabolic status dictate how this instability manifests.

Bottom line

• Nocturnal glycemic swings trigger counter-regulatory spikes in adrenaline and cortisol that cause lighter sleep and micro-arousals, a cycle exacerbated by insulin resistance through impaired hepatic glucose suppression and blunted peripheral clearance.